{
  "cohort": "Medicare NSCLC patients, anti-PD-1 in 2L+ (2024-2025)",
  "insight_type": "Utilization Gap",
  "summary": "Anti-PD-1 utilization in Medicare NSCLC 2L+ is 58%, below NCCN guidance of 65%. Closing this gap could yield $1.8M/year.",
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      { "name": "Provider A", "value": 62, "gap": -3, "highlight": false },
      { "name": "Provider B", "value": 58, "gap": -7, "highlight": false },
      { "name": "Provider C", "value": 45, "gap": -20, "highlight": true },
      { "name": "Provider D", "value": 60, "gap": -5, "highlight": false },
      { "name": "Provider E", "value": 57, "gap": -8, "highlight": false }
    ],
    "benchmark": 65,
    "nccn_target": 65
  },
  "financial_impact": {
    "annual_opportunity": "$1,800,000/year",
    "math": "$1,800,000/year = 120 patients × $15,000 margin per patient"
  },
  "clinical_impact": {
    "description": "Anti-PD-1 therapy improves multiple outcomes in 2L+ NSCLC patients.",
    "metrics": [
      {
        "type": "OS",
        "value": "+13.8 months",
        "description": "Median overall survival benefit"
      },
      {
        "type": "PFS",
        "value": "+8.4 months",
        "description": "Median progression-free survival benefit"
      },
      {
        "type": "5-yr",
        "value": "+21%",
        "description": "Improved 5-year survival rate"
      },
      {
        "type": "AEs",
        "value": "-15%",
        "description": "Reduced severe adverse events"
      },
      {
        "type": "QoL",
        "value": "+18%",
        "description": "Improved quality of life scores"
      }
    ],
    "quantitative": "+13.8 months OS"
  },
  "peer_comparison": {
    "description": "Anti-PD-1 utilization in Medicare NSCLC 2L+ is 58%, below peer average of 72%. Provider C is significantly underperforming at 45%. Closing this gap could yield $2.1M/year.",
    "peer_benchmark": 72,
    "financial_impact": {
      "annual_opportunity": "$2,100,000/year",
      "math": "$2,100,000/year = 140 patients × $15,000 margin per patient"
    },
    "action_steps": [
      {
        "text": "Analyze Provider C's specific barriers to anti-PD-1 utilization",
        "icon": "chart-line"
      },
      {
        "text": "Schedule case review with top performers (Providers A and D)",
        "icon": "calendar"
      },
      {
        "text": "Develop anti-PD-1 peer comparison dashboard",
        "icon": "chart"
      },
      {
        "text": "Implement weekly checkpoint meetings with Provider C",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 95,
  "action_steps": [
    {
      "text": "Identify NSCLC patients eligible for anti-PD-1 therapy",
      "icon": "flag"
    },
    {
      "text": "Focus intervention on Provider C's workflow",
      "icon": "clipboard"
    },
    {
      "text": "Implement PD-L1 testing workflow improvements",
      "icon": "document"
    }
  ],
  "suggestions": [
    {
      "text": "Review Medicare coverage determination process",
      "icon": "document"
    },
    {
      "text": "Develop anti-PD-1 utilization tracking dashboard",
      "icon": "chart"
    }
  ],
  "drilldowns": [
    {
      "label": "View by Payer Type",
      "cohort": "NSCLC patients, anti-PD-1 in 2L+, by Payer",
      "jsonFile": "nsclc-pd1-by-payer.json",
      "drilldownLevel": 1
    },
    {
      "label": "Compare Sites",
      "cohort": "NSCLC patients, anti-PD-1 in 2L+, by Site",
      "jsonFile": "nsclc-pd1-by-site.json",
      "drilldownLevel": 1
    },
    {
      "label": "Variance by Regimen",
      "cohort": "NSCLC patients, anti-PD-1 in 2L+, by Regimen",
      "jsonFile": "nsclc-pd1-by-regimen.json",
      "drilldownLevel": 1
    }
  ]
} 